We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Denosumab

News List

Osteoporosis drug may halve repeat hip replacement procedures: Study expresspharma
January 15, 2021
Researchers from the University of Sheffield and Sheffield Teaching Hospitals found the osteoporosis drug, denosumab, could protect patients from osteolysis, reduce the need for re-operations, and reduce the health burden of this disease.
Common osteoporosis treatments could reduce incidence of COVID-19 europeanpharmaceuticalreview
November 06, 2020
Osteoporosis treatments including denosumab, zoledronate and calcium could protect patients against COVID-19, researchers have said.
First patient enrolled on clinical study for denosumab biosimilar europeanpharmaceuticalreview
July 24, 2019
An integrated Phase I/III trial has enrolled its first patient to test a biosimilar for denosumab to treat postmenopausal osteoporosis.
EU expands scope of Amgen’s Xgeva pharmatimes
July 18, 2018
European regulators have expanded the treatment scope of Amgen’s Xgeva to include the prevention of skeletal-related events in adults with multiple myeloma.
Denosumab reduces glucocorticoid-induced bone loss europeanpharmaceuticalreview
May 02, 2018
The drug denosumab was superior to a commonly used drug in a 12-month study enrolling 795 patients…